News Eikon prices its IPO, seeking to raise $318m Roger Perlmutter's new cancer biotech Eikon has priced its IPO, looking to raise up to $318m and achieve a $900m-plus valuation.
News Lilly allies with gene-editing firm Seamless on hearing loss Gene-editing firm Seamless Therapeutics has attracted its first major pharma partner, Eli Lilly, with a $1.12bn alliance focused on hearing loss.
News Boehringer drug scores in rare kidney disease FSGS Boehringer's TRPC6 inhibitor apecotrep, formerly developed for COVID-19, has shown efficacy in the rare kidney disease FSGS in a phase 2 trial.
News CMS's Medicare price negotiations start round three The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.
News UK biotech sees "strong finish" to 2025 financing 2025 was a challenging year for the UK biotech sector, but it ended the year with signs of "renewed confidence," says the BIA industry body.
News Introducing the Sunday Times Tech 100: Life sciences part 3 In our third and final report on the 2026 Sunday Times Tech 100, we focus on the remaining crop of life sciences companies in the hardware category.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
